Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction to patents
- What makes an invention patentable?
- The meaning of sufficiency
- Sufficiency - key statutory provisions
- Insufficiency in the UK courts (1)
- General principles of sufficiency - UK
- Different forms of insufficiency - UK
- Insufficiency in the UK courts (2)
- Insufficiency in the UK courts (3)
- Insufficiency (1)
- Insufficiency (2)
- Sufficiency - Article 83 EPC
- General principles of sufficiency - EPO
- Plausibility in the EPO
- Glaucoma treatment
- Comparison of sufficiency in the UK and Europe
- Sufficiency of disclosure - US (1)
- Sufficiency of disclosure - US (2)
- Practicalities when preparing a patent specification
- Summary
- Thank you for listening
Topics Covered
- An introduction to patents
- Criteria for an invention to be patentable
- The concepts of sufficiency and insufficiency in patentability
- Sufficiency in the UK compared to Europe
- Discussion of case law in UK, Europe and US
- Practicalities when preparing a patent specification
Links
Categories:
External Links
Talk Citation
Atkinson, J.D. (2021, June 29). Patent sufficiency a UK and European perspective [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VCRY3809.Export Citation (RIS)
Publication History
Financial Disclosures
- Jonathan Atkinson has not informed HSTalks of any conflict of interest.
Patent sufficiency a UK and European perspective
Published on June 29, 2021
28 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Dr. Jonathan Atkinson from HGF Limited in Leeds,
and I am a European patent attorney specialising in the field of pharmaceuticals.
I have a degree and doctorate in Chemistry from Oxford University and
my doctoral thesis concerned the synthesis of chiral derivatives of
morphine-type alkaloids in a stereo-selective manner.
In addition to being a UK and European patent attorney,
I'm also a Fellow of the Royal Society of Chemistry and a Chartered Scientist.
Today I'm going to talk to you about the legal concept of sufficiency in the field of patents.
0:35
Before I delve into the concept of sufficiency,
I will provide a little introduction to the background regarding the nature of a patent itself.
A patent is normally granted for a maximum of 20 years,
apart from in certain exceptional cases in the pharmaceutical industry,
which allow for a longer patent term to compensate for regulatory delays.
All granted patents need to be renewed annually by
payment of renewal fees to the relevant national patent office.
Patents are granted for novel and inventive, i.e. non-obvious subject matter,
and are intended to protect the practical application of
a concept or idea, and not simply the idea itself.
Patents are territorial in nature, this means a patent only has effect in the country in which it was granted.
Finally, the scope of protection afforded by
a patent is defined in the language of the claims
which can be found at the end of a patent specification.
1:29
We can now consider what makes an invention patentable.
There are five fundamental criteria that must be met if a patent is to be granted.
Firstly, the claimed invention must be novel,
which means that the invention must not already be in the public domain.
This has been a subject of a previous Henry Stewart Talk in which
the specific criteria for determining novelty were discussed in more detail.
Basically, an invention must be different in some technical way from what is already known.
The second criterion is that the claimed invention must be inventive,
i.e. must not be obvious, taking into account what is known already.
This has also been the subject of a previous Henry Stewart Talk, in which
the specific criteria for determining inventive steps were discussed in more detail.
In short, the technical difference from what is already known
must not be trivial or obvious to somebody knowledgeable in the field.
The third criterion is that the invention must be sufficient,
i.e. the invention must be adequately described in
the patent specification, so that it can be reproduced by other people.
This is the subject of today's presentation.
Fourthly, the invention must be capable of industrial application.
This criterion is relatively easily met by most commercially-important inventions,
because they are being used for some purpose in industry.
Finally, the fifth criterion is that the invention must not
be one of a number of statutorily-excluded categories,
such as discoveries, mental acts, or computer programs, etc.
These subject matters are deliberately excluded from
patentability by law, as a matter of public policy.
However, in passing, I should mention that there
are certain exceptional cases, when things like computer programs or
other excluded subject matter may be patented, if some technical benefit does arise from them.